GlassScriptPhysician profile
Muhammad Ahmed
NPI 1487848453
$3,167.97
in general payments reported to CMS, 2019-2025
30 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $207 · 2021: $1,079 · 2022: $885 · 2023: $59.04 · 2024: $158 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $488.56 | 2019-2022 | |
| Abbvie INC. | $337.82 | 2021-2022 | |
| Lilly USA, LLC | $228.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $182.63 | 2019-2022 | |
| Boston Scientific Corporation | $157.69 | 2025 | Spyglass Discover |
| Ucb, INC. | $133.89 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.45 | 2019-2023 | |
| Stryker Corporation | $131.27 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $129.84 | 2021 | |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Glaxosmithkline, LLC. | $80.96 | 2019-2024 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $74.03 | 2022 | |
| Pfizer INC. | $62.86 | 2019-2021 | |
| Exact Sciences Corporation | $57.09 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.07 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.20 | 2022 | |
| Dynavax Technologies Corporation | $41.20 | 2024 | Heplisav-B |
| Janssen Biotech, INC. | $32.25 | 2022 | |
| Philips North America LLC | $24.01 | 2022 | |
| Eisai INC. | $23.72 | 2020 | |
| Nevro Corp. | $23.30 | 2024 | Senza |
| Almatica Pharma LLC | $22.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.93 | 2019 | |
| Abbott Laboratories | $15.98 | 2025 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $13.87 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi Pasteur INC. | $13.73 | 2019 | |
| Allergan, INC. | $12.37 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.52 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.